Company / Operating Cash Flow
Supernus Pharmaceuticals, Inc. Operating Cash Flow History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
$47.3M
FY2025
5-year range
$47.3M / $172.0M
FY2021-FY2025
Trend
-72.5%
vs FY2024
Sector context
#62 of 216
Health Care
What the data says
At $47M, Supernus Pharmaceuticals, Inc.'s operating cash flow ranks #62 of 216 in the Health Care sector. Operating Cash Flow has fluctuated over the past 10 years, ranging from -$24M in FY2016 to $172M in FY2024.
Based on SEC 10-K filings.
$47M in FY2025 with a 5-year CAGR of -19.3%.
Declined from $111M to $47M over the past 2 years.
Health Care sector context is included.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -26.0%
- 5-Year CAGR
- -19.3%
- 10-Year CAGR
- -
Sector benchmark
#62 of 216 in Health CareTop 29% of 216This company $47.3M Sector average $658.7M
▼
-92.8% below sector average
Key checks
Key Insights
- 5-year CAGR of -19.3%, indicating a declining trend.
- In FY2025, operating cash flow decreased 72.5% year-over-year.
- Ranks #62 out of 216 companies in the Health Care sector.
- Peak operating cash flow was recorded in FY2024.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $47.3M | -72.5% |
| FY2024 | $172.0M | +54.8% |
| FY2023 | $111.1M | -4.9% |
| FY2022 | $116.8M | -8.1% |
| FY2021 | $127.1M | -8.1% |
| FY2020 | $138.4M | -3.3% |
| FY2019 | $143.1M | +114.2% |
| FY2018 | $66.8M | +93.5% |
| FY2017 | $34.5M | +240.9% |
| FY2016 | -$24.5M | -171.0% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026